JP2023542932A5 - - Google Patents
Info
- Publication number
- JP2023542932A5 JP2023542932A5 JP2023518198A JP2023518198A JP2023542932A5 JP 2023542932 A5 JP2023542932 A5 JP 2023542932A5 JP 2023518198 A JP2023518198 A JP 2023518198A JP 2023518198 A JP2023518198 A JP 2023518198A JP 2023542932 A5 JP2023542932 A5 JP 2023542932A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- approximately
- composition according
- therapeutically effective
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063080165P | 2020-09-18 | 2020-09-18 | |
| US63/080,165 | 2020-09-18 | ||
| US202163159397P | 2021-03-10 | 2021-03-10 | |
| US63/159,397 | 2021-03-10 | ||
| PCT/US2021/050677 WO2022060987A1 (en) | 2020-09-18 | 2021-09-16 | Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023542932A JP2023542932A (ja) | 2023-10-12 |
| JP2023542932A5 true JP2023542932A5 (https=) | 2024-09-25 |
Family
ID=78087574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518198A Pending JP2023542932A (ja) | 2020-09-18 | 2021-09-16 | 常染色体優性低カルシウム血症１型（ａｄｈ１）の治療のためのトリフェニルカルシリティック化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220087961A1 (https=) |
| EP (1) | EP4213829A1 (https=) |
| JP (1) | JP2023542932A (https=) |
| KR (1) | KR20230112609A (https=) |
| AU (1) | AU2021343475A1 (https=) |
| CA (1) | CA3192684A1 (https=) |
| IL (1) | IL301409A (https=) |
| MX (1) | MX2023003129A (https=) |
| TW (1) | TW202227046A (https=) |
| WO (1) | WO2022060987A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230106582A (ko) | 2020-08-04 | 2023-07-13 | 캘시리틱스 테라퓨틱스, 인코포레이티드 | 트리페닐 칼실리틱 화합물의 제형 |
| EP4698162A1 (en) * | 2023-04-21 | 2026-02-25 | Calcilytix Therapeutics, Inc. | Treatment of hypoparathyroidism using triphenyl calcilytic compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0407097A (pt) * | 2003-04-23 | 2006-01-24 | Japan Tobacco Inc | Antagonista do casr |
| KR20230106582A (ko) * | 2020-08-04 | 2023-07-13 | 캘시리틱스 테라퓨틱스, 인코포레이티드 | 트리페닐 칼실리틱 화합물의 제형 |
-
2021
- 2021-09-16 AU AU2021343475A patent/AU2021343475A1/en active Pending
- 2021-09-16 JP JP2023518198A patent/JP2023542932A/ja active Pending
- 2021-09-16 CA CA3192684A patent/CA3192684A1/en active Pending
- 2021-09-16 WO PCT/US2021/050677 patent/WO2022060987A1/en not_active Ceased
- 2021-09-16 US US17/477,198 patent/US20220087961A1/en active Pending
- 2021-09-16 MX MX2023003129A patent/MX2023003129A/es unknown
- 2021-09-16 EP EP21790717.9A patent/EP4213829A1/en active Pending
- 2021-09-16 IL IL301409A patent/IL301409A/en unknown
- 2021-09-16 KR KR1020237012476A patent/KR20230112609A/ko active Pending
- 2021-09-17 TW TW110134985A patent/TW202227046A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11452734B2 (en) | Method of treating and preventing secondary hyperparathyroidism | |
| US7199157B2 (en) | Use of treprostinil to improve kidney functions | |
| EP2648737B1 (en) | Treating conditions associated with increased eotaxin with 25-hydroxyvitamin d3 | |
| JP7177534B2 (ja) | マカ組成物および使用方法 | |
| JP2023542932A5 (https=) | ||
| WO2008058358A2 (en) | Descriptive report of the patent of invention of the medicament 'rosuvastatin + metformin' in combined form for cardiovascular diseases. | |
| US8481514B2 (en) | Therapeutical uses of inecalcitol | |
| WO2008058355A2 (en) | Descriptive report of patent of invention of the medicament 'atorvastatin + metformin' in combined form for cardiovascular diseases | |
| IL321449A (en) | Orforgliferon dosing regimen for the treatment of a patient with type 2 diabetes (T2D), obesity or overweight with at least one weight-related comorbidity | |
| US20210401880A1 (en) | Pharmaceutical Composition For Preventing Or Treating Obesity, Containing CYCLO(HIS-PRO) As Active Ingredient | |
| EP2651251B1 (en) | Composition for the treatment of infertility | |
| US10786514B2 (en) | Dosage regiment of ferric maltol | |
| JPH11502862A (ja) | 腎機能障害患者における燐酸塩過剰血症予防のための１９−ノル−ビタミンｄ化合物の使用 | |
| Brown et al. | Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism | |
| US20100331286A1 (en) | Combination therapy for treatment of bone and mineral disorders for patients with impaired renal function | |
| JP2025031720A5 (https=) | ||
| CN102665421A (zh) | 治疗骨质疏松的方法 | |
| US20210283096A1 (en) | Methods of treating obesity in responder and non-responder populations | |
| US20100305204A1 (en) | Composition useful for the prevention of adverse effect due to the use of ppar-gamma agonists | |
| JP2021020917A (ja) | サクビトリルおよびバルサルタンの組合せの新規使用 | |
| JP2021520403A (ja) | 糖尿病予防・治療用の医薬品組成物及びその用途 | |
| JP2731063B2 (ja) | 卵巣欠落によるのぼせ治療剤 | |
| US20220347141A1 (en) | Methods of treating phosphate concentration disorders with l-baiba | |
| US10105375B2 (en) | Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism | |
| WO2026088203A1 (en) | Synergistic composition for poor muscle health and sarcopenia |